Skip to content

Machine Learning to Predict Acute Care During Cancer Therapy

Generalizable Machine Learning to Predict Acute Care During Outpatient Systemic Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05122247
Acronym
Chemo-SHIELD
Enrollment
12000
Registered
2021-11-16
Start date
2022-01-03
Completion date
2023-09-19
Last updated
2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapeutic Toxicity

Keywords

machine learning, algorithm, outpatient

Brief summary

The objective of this study is to apply a validated machine-learning based model (SHIELD-RT, NCT04277650) to a cohort of patients undergoing systemic therapy as outpatient cancer treatment to generate an automatic system for the prediction of unplanned hospital admission rates and emergency department encounters.

Detailed description

A previously described machine learning (ML)-based model accurately predicted ED visits or hospitalizations for cancer patients undergoing radiation therapy or chemoradiation. An IRB approved prospective randomized trial, SHIELD-RT (NCT04277650) found that preemptive intervention for patients undergoing radiation and chemoradiation based on the ML model's risk stratification decreased the relative risk of acute care visits by 50%, showing that ML-guided escalation of care improved personalized supportive care and treatment compliance while decreasing healthcare costs. The objective of this study is to apply this validated ML based model to a cohort of patients undergoing systemic therapy as outpatient cancer treatment to generate an automatic system for the prediction of unplanned hospital admission rates and emergency department encounters. Once validated, this study will add to the previously published body of evidence supporting a randomized trial evaluating the ML algorithm's ability to assign intervention for patients receiving systemic therapy at highest risk for acute care encounters.

Interventions

machine learning directed identification of chemotherapy patients at high-risk for emergency department acute care and/or hospitalization

Sponsors

University of California, San Francisco
CollaboratorOTHER
Duke University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* had treatment encounter in the Duke Medical Oncology department from January 7th, 2019 to June 30th, 2019 * DUHS medical record available

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
number of unplanned of hospital admission or emergency department visits during systemic therapy12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026